On June 23, 2020, the American Association for Cancer Research (AACR) announced that treatment with the personalized cancer vaccine RO7198457 (https://www.cancer.gov/publications/dictionaries/cancer-drug/def/personalized-cancer-vaccine-ro7198457), in combination with the PD-L1 immune checkpoint inhibitor atezolizumab (Tecentriq), was well-tolerated and showed clinical benefit in patients with advanced solid malignancies, according to results from a phase 1b clinical trial (https://clinicaltrials.gov/ct2/show/NCT03289962 ) presented at the AACR 2020 Virtual Annual Meeting II (https://www.aacr.org/meeting/aacr-annual-meeting-2020/aacr-virtual-annual-meeting-ii/), held June 22-24. “Many cancers are able to successfully avoid the immune system, and we are only starting to understand the myriad ways in which cancers can do this,” said Juanita Lopez (photo), PhD, MB BChir (https://www.royalmarsden.nhs.uk/our-consultants-units-and-wards/consultant-directory/dr-juanita-suzanne-lopez), a physician/scientist who is a Consultant Medical Oncologist at the Phase I Drug Development Unit at the Royal Marsden National Health Services (NHS) Foundation Trust (UK) and the Institute of Cancer Research, specializing in early phase translational drug development and the treatment of patients with brain tumors. Dr. London presented the trial results on Tuesday morning, June 23, during the AACR meeting. The presentation (CT301) was titled “A Phase Ib Study to Evaluate RO7198457, an Individualized Neoantigen Specific Immunotherapy (iNeST), in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors” (https://www.abstractsonline.com/pp8/#!/9045/presentation/11339).Login Or Register To Read Full Story